Company: MIRA
Filing Date: 2025-04-16
Form Type: 424B5
Source: 0001641172-25-005104
Chunk: 0

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-04-16
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-281467

PROSPECTUS SUPPLEMENT

(To Prospectus Supplement dated September 26, 2024

to Prospectus dated August 16, 2024)

<div align='center'>Up to $7,034,658

Common Stock</div>

This prospectus supplement (the “Prospectus Supplement”) amends and supplements the information in the prospectus dated August 16, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-281467) (the “Registration Statement”) and base prospectus contained therein (the “August Prospectus”), and the prospectus supplement dated September 26, 2024 (the “September Prospectus Supplement” and together with the August Prospectus, the “Prior Prospectus”), relating to the offering, issuance and sale by us of our common stock, par value $0.0001 per share (“Common Stock”), from time to time that may be issued and sold under the at the market offering agreement (the “Sales Agreement”), dated August 12, 2024, and amended on September 24, 2024, by and between us and Rodman & Renshaw LLC, as sales agent. This Prospectus Supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.

We are filing this Prospectus Supplement to amend the Prior Prospectus to update the maximum amount of shares we are eligible to sell pursuant to the Prospectus. We are filing this Prospectus Supplement to amend and supplement the Prior Prospectus because as of the date we filed our Annual Report on Form 10-K for the year ended December 31, 2024, our Registration Statement became subject to the offering limits set forth in General Instruction I.B.6 of Form S-3, which limits the amounts that we may sell under the Registration Statement of which this Prospectus Supplement and the Prior Prospectus form a part. As of the date hereof, the current aggregate market value of our outstanding Common Stock held by non-affiliates, or public float, is $21,103,974, which was calculated based